BioSpace News Archive

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”), a leader in pharmaceutical films, today announced that the U.S. Food and Drug Administration (”FDA”) has accepted for review its Class 2 response to the 2020 Complete Response Letter for its 505(b)(2) New Drug Application (“NDA”) for RIZAFILM ® VersaFilm ® .

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences: Evercore ISI 5th Annual HealthCONx Virtual Conference Tuesday, November 29, 2022 Fireside chat at 10:55 am Eastern Time.

Vera Therapeutics, Inc. today announced that the Company’s management team will present and participate in one-on-one meetings at the following investor conferences.

Sensei Biotherapeutics, Inc. today announced that John Celebi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held in New York, NY, on Thursday, December 1, 2022, at 2:00 p.m. ET.

Vivos Therapeutics, Inc today provided an update on its review of the Company’s revenue recognition policies and the expected timing for the release of its second and third quarter 2022 financial results.

Syros Pharmaceuticals today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.

Calyx announced that a Top 10 pharmaceutical company is leveraging medication pooling, an advanced inventory management strategy available through Calyx IRT, to improve drug distribution efficiencies and reduce drug wastage in an ongoing, global clinical development program.

Avadel Pharmaceuticals plc announced today that members of management will participate in the following upcoming investor conferences.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Adrian Gottschalk, President and Chief Executive Officer, will participate in the Evercore ISI HealthCONx Conference which will be held virtually on November 30, 2022.

Achilles Therapeutics plc today announced that United States (US) patent 11,504,398 has been granted.